Loading…
Aldeyra Therapeutics, Inc. is projected to rise to $1.93 by 2027, a +26% move from its current price of $1.54. ALDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.48 | $1.54 | $1.61 | +0.09% |
| Aug 6 | $1.45 | $1.54 | $1.64 | +0.18% |
| Aug 7 | $1.43 | $1.54 | $1.66 | +0.28% |
| Aug 8 | $1.42 | $1.55 | $1.69 | +0.37% |
| Aug 9 | $1.40 | $1.55 | $1.70 | +0.46% |
| Aug 10 | $1.39 | $1.55 | $1.72 | +0.55% |
| Aug 11 | $1.38 | $1.55 | $1.74 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.38 | $1.55 | $1.74 | +0.65% |
| Week 2 | $1.33 | $1.56 | $1.83 | +1.30% |
| Week 3 | $1.29 | $1.57 | $1.91 | +1.96% |
| Week 4 | $1.26 | $1.58 | $1.99 | +2.62% |
| Week 5 | $1.23 | $1.59 | $2.05 | +3.28% |
| Week 6 | $1.21 | $1.60 | $2.12 | +3.95% |
| Week 7 | $1.19 | $1.61 | $2.18 | +4.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis.
The company also develops ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. It also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX is a Healthcare stock currently priced at $1.55 with a market cap of $93.5M and a rank of 4136. The stock operates in the biotechnology space, focusing on immune-mediated disease therapies and RASP modulation.
The forecast outlook suggests a path of gradual price growth, starting with an average of $1.55 in 2026 and rising to $2.42 by 2030, then climbing to an average of $19.04 by 2050, with corresponding ROIs rising from 0% to 1128.4% over the period. Sentiment shifts from NEUTRAL in 2026 to BULLISH from 2027 onward.
A major floor 40.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 57.8% above — a clean break opens room to run.
A major ceiling 77.9% above — clearing it would confirm fresh momentum.
Key ALDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.58 | Sell | $1.58 | Sell |
| MA 10 | $1.61 | Sell | $1.64 | Sell |
| MA 20 | $1.82 | Sell | $1.73 | Sell |
| MA 50 | $1.82 | Sell | $1.86 | Sell |
| MA 100 | $1.90 | Sell | $2.26 | Sell |
| MA 200 | $3.47 | Sell | $2.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.34 | Neutral |
| Stoch RSI (14) | 18.46 | Buy |
| CCI (20) | -81.78 | Neutral |
| Williams %R (14) | -95.12 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -19.79 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 4.88 | Buy |
| TRIX (15) | -0.51 | Sell |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 27.49 | Buy |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 1.58 | Sell |
| ADX (14) | 19.25 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40, with a SMA50 of $1.83 and a SMA200 of $3.59. Support is at $1.55 and resistance at $2.43, framing a near-term range.
The 30-day range spans from $1.11 to $2.16, indicating a modest trading band around the current level. This setup suggests continued consolidation near the current price with a tighter footing near support, while resistance at $2.43 could cap upside in the immediate term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.24 | $1.54 | $2.34 | 0% | Neutral | |
| $1.46 | $1.93 | $2.75 | +26% | Bullish | |
| $1.46 | $2.03 | $3.06 | +32% | Bullish | |
| $1.49 | $2.16 | $3.39 | +40% | Bullish | |
| $1.37 | $2.05 | $3.33 | +33% | Bullish | |
| $1.61 | $2.50 | $4.18 | +62% | Bullish | |
| $1.93 | $3.08 | $5.30 | +100% | Bullish | |
| $2.07 | $3.40 | $5.99 | +121% | Bullish | |
| $2.38 | $4.04 | $7.28 | +162% | Bullish | |
| $2.12 | $3.69 | $6.77 | +139% | Bullish | |
| $3.11 | $6.18 | $12.34 | +301% | Bullish | |
| $4.89 | $10.87 | $24.45 | +606% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.24 | $1.54 | $1.94 | +0.00% |
| September 2026 | $1.32 | $1.58 | $1.98 | +2.77% |
| October 2026 | $1.38 | $1.68 | $2.13 | +5.85% |
| November 2026 | $1.46 | $1.80 | $2.31 | +7.33% |
| December 2026 | $1.45 | $1.80 | $2.34 | +0.12% |
Click any year to see its month-by-month ALDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ALDX could reach as high as $2.34, with a base case around $1.54 and support toward $1.24 — roughly 0% from $1.54. Price action looks broadly range-bound.
Expect ALDX to range from $1.46 to $2.75 through 2027. The $1.93 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ALDX price prediction for 2028 points to an average of $2.03 (low $1.46, high $3.06) — a potential gain of +32% on today's $1.54. Momentum favours further upside here.
In 2029, ALDX is projected to trade between $1.49 and $3.39, averaging $2.16 — a potential gain of +40% from today's $1.54. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Aldeyra Therapeutics, Inc.'s 2030 outlook centres on $2.05, within a $1.37 to $3.33 range. That is -5% versus the projected 2029 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2031, ALDX could reach as high as $4.18, with a base case around $2.50 and support toward $1.61 — roughly +62% from $1.54. Buyers look set to stay in control over this stretch.
Expect ALDX to range from $1.93 to $5.30 through 2032. The $3.08 average target implies a +100% move from current prices. That is up +23% on the projected 2031 average. Momentum favours further upside here.
The ALDX price prediction for 2033 points to an average of $3.40 (low $2.07, high $5.99) — a potential gain of +121% on today's $1.54. Buyers look set to stay in control over this stretch.
In 2034, ALDX is projected to trade between $2.38 and $7.28, averaging $4.04 — a potential gain of +162% from today's $1.54. That is up +19% on the projected 2033 average. Momentum favours further upside here.
Aldeyra Therapeutics, Inc.'s 2035 outlook centres on $3.69, within a $2.12 to $6.77 range. That is -9% versus the projected 2034 average. That marks a +139% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ALDX could reach as high as $12.34, with a base case around $6.18 and support toward $3.11 — roughly +301% from $1.54. Momentum favours further upside here.
Expect ALDX to range from $4.89 to $24.45 through 2050. The $10.87 average target implies a +606% move from current prices. That is up +76% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALDX today (≈ 649.350649 ALDX) could be worth
$7,055.72
+$6,055.72 (+606%) by 2050 · US Dollar
Based on the average projected ALDX price of $10.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALDXwould be worth at today's price.
$1,000 invested in ALDX on Jul 31, 2025 (≈ 200.400811 ALDX) would be worth
$308.62
-$691.38 (-69.1%) today · 0.31× · US Dollar
Based on a ALDX entry price of $4.99 vs. today's $1.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.52 | $1,013.16 | +1.3% |
| 1 month ago | $2.43 | $633.74 | -36.6% |
| 3 months ago | $1.59 | $968.55 | -3.1% |
| 6 months ago | $5.43 | $283.61 | -71.6% |
| 1 year ago | $4.99 | $308.62 | -69.1% |
| All time (5.0y) ago | $9.57 | $160.92 | -83.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALDX forecast.
Our base-case forecast reaches $3.10 around 2033.
Implied market cap at $3.10: $187M
The multi-year forecast paints a bullish trajectory after 2026. By 2027 the average price is projected at $2.05 with a 32% ROI, rising to $3.00 max in 2027 and higher in subsequent years. By 2028 the average is $2.19 with a 41.5% ROI, and by 2029 an average of $2.40 with a 54.9% ROI, culminating in 2030 with an average of $2.42 and a 56.1% ROI.
The forecast continues with 2031 at an average of $3.20 (106.5% ROI), 2032 at $4.14 (167.1% ROI), 2033 at $4.64 (199.7% ROI), 2034 at $5.57 (259.1% ROI), and 2035 at $4.94 (218.6% ROI). The longer-horizon view shows substantial upside, with 2040 averaging $9.54 (515.5% ROI) and 2050 averaging $19.04 (1128.4% ROI).
Key drivers cited in the forecast include reproxalap in Phase III for dry eye disease and allergic conjunctivitis, ADX-629 in Phase 2, and the ongoing development of preclinical RASP platforms (ADX 248, ADX 246, and others). Risks include the inherent uncertainties of clinical development and regulatory outcomes that can impact the trajectory of any biotech stock. These figures are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
Avg price $2.42; Min $1.54; Max $4.11; ROI 56.1%; Sentiment BULLISH.
The forecast shows a bullish path from 2027 onward, with 2027 avg $2.05 and ROI 32%, rising through 2030 to avg $2.42 and ROI 56.1%, and by 2050 to avg $19.04 with ROI 1128.4%. 2026 is neutral with avg $1.55 and ROI 0%.
Yes. The forecast max price reaches $10.58 in 2034 and $20.32 in 2040 (2034 max $10.58; 2040 max $20.32).
Current price $1.55; market cap $93.5M.
Low $1.11; High $2.16.
Aldeyra Therapeutics, Inc. Community Discussion
0Share your Aldeyra Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.